Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 JUL 20 ... of the functional response of brain metastasis to the anti-VEGF receptor therapeutic, AZD2171 (Cediranib, RECENTIN (TM)). MR tracking of individual cells demonstrated that cediranib ...
2009 JUL 27 ... diffuse-type gastric cancer, and endometrial uterine cancer. Oral administration of AZD2171 or Ki23057 inhibits in vivo proliferation of cancer cells with aberrant FGFR2 activation ...
2009 JUL 27 ... tumorigenesis." "It is tightly regulated by the VEGF system. Cediranib (AZD2171, Recentin (TM); AsfraZeneca, London, UK) is a novel and potent small-molecule inhibitor ...
2008 APR 28 ... and ovarian cancers and lymphoma.
A Multidisciplinary Phase II Study of AZD2171 (cediranib), an Oral Pan-VEGF Receptor Tyrosine Kinase Inhibitor, in Patients with ...
2008 AUG 4 ... However, their potency toward individual targets can vary. Cediranib (RECENTIN; AZD2171) is an inhibitor of VEGF signaling that has been shown in experimental models to prevent ...
2008 SEP 1 ... but counteract during osteogenesis and adipogenesis. Among PD173074, SU5402, and AZD2171 functioning as FGFR inhibitors, AZD2171 is the most ...
2007 OCT 29 ... According to recent research from Freiburg, Germany, "' AZD2171 is a highly potent oral selective inhibitor of vascular endothelial growth factor ( ...
2007 NOV 12 ... vascular endothelial growth factor signaling system inhibiting agents bevacizumab and AZD2171 (cediranib) that showed high response rates (which might be due to vessel normalization ...
2007 OCT 1 ... Researchers detail in "Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in ...
2007 OCT 15 ... Study 1: Researchers detail in "Phase I dose escalation and pharmacokinetic study of AZD2171, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinase, in ...
2007 DEC 3 ... it is likely that agents with multiple targets (e.g. sunitinib, sorafenib, ZD6474, AZD2171 and AMG 706) may have greater activity than those with single-target activity through ...
2008 JUL 7 ... factor-A signaling induces hypertension: Examining the effect of cediranib (Recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant anti hypertensive ...
